Introduction: the scientific and clinical rationale for extended acid suppression

被引：0
|
作者：
Katz, Philip O. [1 ]
机构：
[1] Albert Einstein Med Ctr, Div Gastroenterol, Philadelphia, PA 19141 USA
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2006年 / 23卷
关键词：
D O I：
10.1111/j.1365-2036.2006.02942.x
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 50 条
  • [11] Lack of scientific rationale for use of valproic acid for retinitis pigmentosa
    Sandberg, Michael A.
    Rosner, Bernard
    Weigel-DiFranco, Carol
    Berson, Eliot L.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2011, 95 (05) : 744 - 744
  • [12] Intermittent androgen suppression for prostate cancer: Rationale and clinical experience
    Gleave, M
    Bruchovsky, N
    Goldenberg, SL
    Rennie, P
    EUROPEAN UROLOGY, 1998, 34 : 37 - 41
  • [13] SCIENTIFIC RATIONALE AND CLINICAL IMPLICATIONS OF SUSTAINED-RELEASE FORMULATIONS
    KELLAWAY, IW
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1988, 42 (04): : 9 - 13
  • [14] Intermittent androgen suppression for prostate cancer: rationale and clinical experience
    Gleave, M
    Goldenberg, SL
    Bruchovsky, N
    Rennie, P
    PROSTATE CANCER AND PROSTATIC DISEASES, 1998, 1 (06) : 289 - 296
  • [15] Intermittent androgen suppression for prostate cancer: rationale and clinical experience
    M Gleave
    SL Goldenberg
    N Bruchovsky
    P Rennie
    Prostate Cancer and Prostatic Diseases, 1998, 1 : 289 - 296
  • [16] Metastatic melanoma:: Scientific rationale for sorafenib treatment and clinical results
    Egberts, Friederike
    Kaehler, Katharina C.
    Livingstone, Elisabeth
    Hauschild, Axel
    ONKOLOGIE, 2008, 31 (07): : 398 - U6
  • [17] Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
    Natalia Timofeeva
    Varsha Gandhi
    Blood Cancer Journal, 11
  • [18] Combination therapies for multiple sclerosis:: scientific rationale, clinical trials, and clinical practice
    Costello, Fiona
    Stuve, Olaf
    Weber, Martin S.
    Zamvil, Scott S.
    Frohman, Elliot
    CURRENT OPINION IN NEUROLOGY, 2007, 20 (03) : 281 - 285
  • [19] Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
    Timofeeva, Natalia
    Gandhi, Varsha
    BLOOD CANCER JOURNAL, 2021, 11 (04)
  • [20] Introduction and rationale
    Schofield, Nick
    Turner, Jonathan P.
    Underhill, John R.
    PETROLEUM GEOSCIENCE, 2009, 15 (03) : 195 - 196
12345